课题基金 / 基金详情

PHASE I OF LY309887 IN PATIENTS WITH METASTATIC CANCER

PHASE I OF LY309887 IN PATIENTS WITH METASTATIC CANCER
LY309887 在转移性癌症患者中的 I 期治疗
批准号：
5223267
负责人：
JOHN ECKARDT
金额：
$0.0万
依托单位：
--
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/5223267
关键词：
antineoplastics clinical research clinical trial phase I dosage drug screening /evaluation enzyme inhibitors folate human subject metastasis nutrient drug interaction nutrition related tag pharmacokinetics vitamin biosynthesis

项目摘要

项目成果

JOHN ECKARDT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
LY309887 is an inhibitor of the enzyme glycinamide ribonucleotide formyltransferase, which is involved in de novo folic acid synthesis. The purpose of the phase I study is to determine the MTD of LY309887 as a single dose given IV once every 21 days with folic acid supplementation given orally 2 days before, on the day of, and for 2 days after administration.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE I OF BCNU AND TEMOZOLOMIDE
PHASE I OF LY309887 IN PATIENTS WITH METASTATIC CANCER
PHASE I STUDY OF TOREMIFENE AND DOXORUBICIN IN PATIENTS WITH ADVANCED CANCER
PHASE I STUDY OF TOREMIFENE AND DOXORUBICIN IN PATIENTS WITH ADVANCED CANCER
海外基金